Upload File

complex t2 dm patients with multiple comorbidities safety considerations for dpp 4 inhibitors

  • Home
  • Documents
  • Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
23

Upload: mikayla-vargas

Post on 31-Dec-2015

15 views

Category:

Documents


0 download

Report

DESCRIPTION

- PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 2: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 3: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 4: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 5: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 6: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 7: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 8: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 9: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 10: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 11: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 12: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 13: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 14: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 15: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 16: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 17: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 18: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 19: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 20: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 21: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 22: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors
Page 23: Complex T2 DM patients with multiple comorbidities Safety considerations for DPP 4 inhibitors

2018 ANNUAL TREND REPORT...As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors due to their ability to reduce

Ra comorbidities

The place of DPP-4 inhibitors in the treatment algorithm ...€¦ · the country and year of each study, DPP-4 inhibitors were highly cost-effective as second-line, as add-ons to

A New Therapy of Type 2 Diabetes: DPP-4 Inhibitorscdn.intechweb.org/pdfs/21462.pdf1 A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors Tatjana Ábel National Health Center Hungary

1 The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

Janos Fischer-Serendipitous Target-based Drug Discovery · Drug therapy of type 2 of diabetes with DPP-4 inhibitors 2001 sitagliptin : pioneer DPP-4 inhibitor (QD) 1998 vildagliptin

Switching Therapy to Integrase Inhibitors in Patients with ...regist2.virology-education.com/presentations/2019/HIVClinicalForum… · Comorbidities of Newly Diagnosed HIV Patients

Medication Management in Diabeteswadepage.org/files/2019Conf/WADE_DM meds_Emerging_Newsome_Updated.pdfAdministration Subcutaneous Oral Gallwitz B. EurEndocr Dis 2006:43-46. DPP-4 Inhibitors:

PharmEvo Diabetes & DPP-4 Inhibitors Workshop 2013

A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors

Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors

CA D TH ISSUES IN EMERGING HEA LT H TECHNOLO GIES...CV outcomes and all drugs in the following classes: DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists. Methodological

Comorbidities in Cerebr

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review … · 2019. 7. 30. · Review Article DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus:

Comparative Safety and Effectiveness of Type 2 …€¦ · Web viewBennett 2011 did not include sodium glucose co-transporter 2 (SGLT2) inhibitors or DPP-4 inhibitors.1 Therefore,

PHARMACOLOGICAL MANAGEMENT OF PATIENTS WITH TYPE 2 …ijsit.com/admin/ijsit_files/PHARMACOLOGICAL MANAGEMENT OF... · 2019-03-02 · f) DPP-4 inhibitors: The DPP-4 Inhibitors is not

ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah

The effects of DPP-4 inhibitors on vascular endothelial function in … · 2016. 5. 4. · The effects of DPP-4 inhibitors on vascular endothelial function in diabetes A thesis submitted

Combining MK626, a Novel DPP-4 Inhibitor, and Low- Dose ... · strategy in type 1 diabetes cure. Dipeptidyl peptidase-4 (DPP-4) inhibitors elevate circulating levels of active incretins,

Comparison of efficacy between different incretin based ... Comparison of efficacy between different incretin-based therapies; GLP-1 agonists and DPP-4 inhibitors. Kaustubh Nisal1,

DPP 2011 Vs. DPP 2009 and DPP 2008

Normal Fuel Metabolism - Amazon Web Servicesenp-network.s3.amazonaws.com/NPA_Syracuse/file/... · • DDP-4 inhibitors: 4 medications plus 7 combinations Dipeptidyl peptidase-4 (DPP-4)

The effects of DPP-4 inhibitors on vascular endothelial ...researchbank.rmit.edu.au/view/rmit:161445/Salheen.pdf · The effects of DPP-4 inhibitors on vascular endothelial function

2018 ANNUAL TREND REPORT · 2020-04-30 · FOCUS ON DIABETES As predicted in our 2016 Trend Report, GLP-1 agonist and SGLT2 inhibitors have gained more market share than DPP-IV inhibitors

Research Article Renal Protective Effect of DPP-4 ...downloads.hindawi.com/journals/jdr/2016/1423191.pdf · Research Article Renal Protective Effect of DPP-4 Inhibitors in Type 2

Differences in the glucose-lowering efficacy of dipeptidyl ... · 1c-lowering efficacy of DPP-4 inhibitors at the end of the study. Secondary outcomes were the effect of DPP-4 inhibitors

Efficacy and safety of dipeptidyl peptidase-4 inhibitors · DPP-4 inhibitors did not induce a higher rate of hy - poglycemia (RR=1.31, 95%CI: 0.97, 1.77; p =0.075). CONCLUSIONS: DPP-4

Dipeptidyl peptidase 4 (DPP-4) inhibitors and ......Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over

Incretinas, Incretinomiméticos, Inhibidores de DPP IV ... · Incretinas, Incretinomiméticos, Inhibidores de DPP IV – 1er parte Incretins, Incretinmimetics, Inhibitors ... dicho

Dipeptidyl Petidase-4 (DPP-4) Inhibitors - Utah … currently available DPP-4 inhibitors in the US include sitagliptin (Januvia), saxagliptin (Onglyza), linaglitin (Tradjenta), and

Type 2 Diabetes Treatment: Novel Therapies GLP-1 Receptor Agonists/Analogs and DPP-4 Inhibitors Jaime A. Davidson, MD, FACP, MACE Clinical Professor of

 · Web viewThree dipeptidyl-peptidase 4 (DPP-4) inhibitors are currently available in the United States: sitagliptin, saxagliptin and linagliptin. None of the DPP-4 inhibitors are

Side Effects of · 2018-04-29 · Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · 2020-05-23 · Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria

Dr Brandon Orr-Walker - GP CME North/Sat_Plenary_1215_Orr... · 2018-06-09 · Side Effects: GLP-1 Receptor Agonists and DPP-4 Inhibitors GLP-1 Receptor Agonists DPP-4 Inhibitors